Baseline Data
From April 6, 2023, to December 28, 2023, 242 patients were screened at 22 centers in China, and 173 patients were ultimately enrolled (86 subjects were randomly assigned to the experimental group to receive MRG003, and 87 subjects were randomly assigned to the control group to receive capecitabine/docetaxel); 33 patients in the control group crossed over to receive MRG003 treatment after disease progression (PD) (Figure 1).
A brief description of the baseline characteristics of the study subjects is provided in Table 1. The baseline characteristics were balanced between the two groups.
